NCT00308048|CompletedPhase 3
Loading search results
Sponsor study identifier
interventional
435
1 country
1
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Patients with HCV genotype 2 or 3 infection who have a rapid virological response to treatment are randomised to either 14 or 24 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
March 27, 2006
Actual (reported)March 28, 2006
Actual (reported)September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Sustained virological response (SVR) =HCV RNA negativity (<20 IU/ml) six months after end of treatment.
Change in health related quality as measured by short from 36 (SF-36) from baseline to 6 months after end of treatment.
Sick leave in patients treated for 14 or 24 weeks treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
Pegylated Interferon alfa 2b and ribavirin
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordUllevaal University Hospital
Oslo, 0407, Norway
Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, Raknerud N, Bell H. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology. 2004 Dec;40(6):1260-5. doi: 10.1002/hep.20467.
Olav Dalgard, MD PhD
Ullevaal University Hospital, Oslo, Norway
First Submitted
March 27, 2006
First Posted
March 28, 2006
Study Start
March 2004
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
September 2006
Date type not reportedContact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
July 6, 2011
Record last verified: 2006-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: